Carlson Capital’s enGene Therapeutics ENGN Stock Holding History
Bought
Maintained
Sold
Other funds holding ENGN
BCM
SL
ACA
Carlson Capital's ENGN Position: Q3 2026 in Review
Carlson Capital opened a new position in enGene Therapeutics (ENGN) in Q3 2026: 50,000 shares worth $100K. The stake represents 0.02% of the portfolio and ranks #84 among its holdings.
60 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.
- Carlson Capital held 50,000 shares of enGene Therapeutics worth $100K as of Q3 2026.
- enGene Therapeutics was a new Carlson Capital position in Q3 2026.
- enGene Therapeutics made up 0.02% of Carlson Capital's portfolio in Q3 2026, its #84 holding.
- 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.
Based on Carlson Capital's 13F filing for Q3 2026, filed 9 Nov 2026.